CJC-1295 vs HGH Fragment 176-191
CJC-1295 (GHRH analog (long-acting, with Drug Affinity Complex / DAC)) and HGH Fragment 176-191 (Modified GH-fragment peptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | CJC-1295 | HGH Fragment 176-191 |
|---|---|---|
| Compound class | GHRH analog (long-acting, with Drug Affinity Complex / DAC) | Modified GH-fragment peptide |
| Research category | Growth & GH-Axis | Metabolic & Mitochondrial |
| Length (amino acids) | 30 amino acids | 15 amino acids |
| Molecular weight | Approximately 3647 g/mol (with DAC linker) | ~1817 g/mol |
| Half-life | Substantially extended vs native GHRH; reported on the order of days (approximately 6-8 days) due to albumin binding via DAC | ~15-20 minutes (reported) |
| Origin | CJC-1295 (with DAC) is a synthetic long-acting GHRH analog based on a modified GHRH(1-29) sequence, developed by ConjuChem. It incorporates a Drug Affinity Complex (DAC) that binds serum albumin to greatly extend circulating half-life. | HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region (residues 176-191) of human growth hormone. This portion of the GH molecule was identified as carrying the hormone's lipolytic activity. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How CJC-1295 works
CJC-1295 is a GHRH-receptor agonist that stimulates pulsatile GH secretion from the pituitary. Its GHRH(1-29) backbone carries stabilizing amino-acid substitutions (e.g. at positions 2, 8, 15, 27) that resist DPP-4 degradation, and the DAC group forms a covalent bond with albumin, dramatically prolonging its action. This produces a sustained elevation of GH and IGF-1 rather than sharp discrete pulses.
How HGH Fragment 176-191 works
The fragment reproduces the C-terminal, lipolytic-associated region of GH while lacking the domains responsible for GH's growth-promoting and insulin-antagonizing actions. In preclinical models this region has been reported to stimulate fat breakdown (lipolysis) and reduce lipogenesis. It is not intact growth hormone and is not reported to reproduce GH's systemic growth effects.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
CJC-1295
HGH Fragment 176-191
What sets each apart
CJC-1295
The DAC version's albumin binding gives it a far longer half-life (days) than the no-DAC 'Mod GRF 1-29' (minutes), making it the long-acting member of the CJC-1295 family.
HGH Fragment 176-191
This is the native GH C-terminal fragment; AOD-9604 is its modified, tyrosine-extended analog. Both isolate lipolytic activity away from full GH signaling.
Frequently asked questions
What is CJC-1295 (with DAC)?
CJC-1295 is a synthetic long-acting analog of GHRH(1-29). This slug refers to the DAC (Drug Affinity Complex) version, which carries a maleimidopropionic acid linker that covalently binds serum albumin after injection, dramatically extending its circulating half-life to several days.
What is the difference between CJC-1295 with DAC and without DAC?
Both share the same modified 29-amino-acid GHRH core with substitutions that resist DPP-IV cleavage. The DAC version adds an albumin-binding complex giving a half-life of roughly 6-8 days, producing a sustained 'GH bleed,' whereas the no-DAC version (Mod GRF 1-29) has only a ~30 minute half-life and produces discrete pulses.
What does the long half-life mean for research design?
Because CJC-1295 with DAC persists for days, it raises the baseline of GHRH tone rather than producing sharp pulses. In research this is described as elevating overall GH and IGF-1 output; studies often examine how this sustained tone interacts with pulsatile GHRP stimulation.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal lipolytic region (residues 176-191) of human growth hormone (native sequence LRIVQCRSVEGSCGF). Research identified this segment as carrying the fat-mobilizing activity of GH, while the diabetogenic IGF-1-driving activity resides in a different region (roughly 1-43).
How does HGH Fragment 176-191 differ from AOD-9604?
AOD-9604 is a stabilized analog of HGH Fragment 176-191: it adds an N-terminal tyrosine to the native fragment to improve stability and lipolytic activity. HGH Fragment 176-191 is the unmodified sequence. Both are studied for lipolysis, but the raw fragment is less characterized and has a very short duration.
What does the short half-life imply for research design?
The fragment has a very short half-life (reported ~15-20 minutes), which is why research protocols often describe split dosing (e.g., morning and evening) to maintain exposure. Its rapid clearance is an important consideration when designing pharmacodynamic experiments around lipolysis.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.